0000950123-17-009332.txt : 20171030 0000950123-17-009332.hdr.sgml : 20171030 20171030165930 ACCESSION NUMBER: 0000950123-17-009332 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171030 DATE AS OF CHANGE: 20171030 EFFECTIVENESS DATE: 20171030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biomark Capital Management Co. LLC CENTRAL INDEX KEY: 0001667082 IRS NUMBER: 463904521 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-17353 FILM NUMBER: 171163055 BUSINESS ADDRESS: STREET 1: 537 STEAMBOAT RD., SUITE 200 CITY: GREENWICH STATE: CT ZIP: 06830 BUSINESS PHONE: 203-769-2345 MAIL ADDRESS: STREET 1: 537 STEAMBOAT RD., SUITE 200 CITY: GREENWICH STATE: CT ZIP: 06830 13F-HR 1 primary_doc.xml 13F-HR LIVE false true false 0001667082 XXXXXXXX 09-30-2017 09-30-2017 Biomark Capital Management Co. LLC

537 STEAMBOAT RD., SUITE 200 GREENWICH CT 06830

13F HOLDINGS REPORT 028-17353 Y The filing of this report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g), or 16(a) under the Securities Exchange Act of 1934, as amended, and the rules thereunder, or for any other purpose, that the Reporting Manager or any other person (including Other Managers or Other Included Managers named herein) is the beneficial owner of any securities. Biomark Capital Management Co. LLC, a Delaware limited liability company (the "Management Company"), is an institutional investment manager which, for the purposes of Section 13(f) of the Securities Exchange Act of 1934 and the rules promulgated thereunder ("Section 13(f)"), exercises investment discretion with respect to certain securities positions held directly and indirectly by Biomark Capital Fund IV LP, a Delaware limited partnership (the "Fund"). David S. Wetherell, an individual ("Wetherell") and Biomark Capital Fund IV GP LLC, a Delaware limited liability company (the "General Partner"), may each be deemed to exercise investment discretion over the securities reported on this Form 13F for purposes of Section 13(f). Certain of the security positions reported by the Management Company are also being reported by Wetherell and the General Partner. Also, 99,384 shares of common stock of Juno Therapeutics, Inc. reported by the Management Company are held by a majority owned portfolio company of the Fund. Each of the Management Company, the General Partner and Wetherell disclaims beneficial ownership of the shares reported on this Form 13F by the Management Company except to the extent of any pecuniary interest therein. David S. Wetherell (203) 769-2345 /s/ David S. Wetherell Boston MA 10-30-2017 2 3 88059 false 1 28-17351 Biomark Capital Fund IV GP LLC 2 28-17354 David S. Wetherell INFORMATION TABLE 2 form13fInfoTable.xml INFORMATION TABLE FOR FORM 13F JUNO THERAPEUTICS, INC. COM 48205A109 83627 1864174 SH OTR 1764790 99384 0 MABVAX THERAPEUTICS HOLDINGS, INC. COM NEW 55414P504 17 26708 SH OTR 26708 0 0 ADMA BIOLOGICS, INC. COM 000899104 4415 1433304 SH OTR 1433304 0 0